<DOC>
	<DOCNO>NCT00814372</DOCNO>
	<brief_summary>To define relative efficacy , safety tolerability profile oral daily MBX-102 daily dose 400 600 mg vs. placebo Actos® 30 mg ( up-titrated 45 mg 8 week ) administer 24 week patient inadequately control stable dose metformin ( ≥ 1500 mg/day ) .</brief_summary>
	<brief_title>Evaluate Safety Effectiveness MBX-102 Type 2 Diabetes Patients With Poor Glycemic Control Metformin</brief_title>
	<detailed_description>Approximately 240 patient randomize study , 60 two MBX-102 treatment group ( 400 600 mg daily ) , 60 placebo , 60 Actos® group . Patients Actos® group receive Actos® 30 mg/daily first eight week treatment phase Actos® 45 mg/daily last 16 week treatment phase . Patients MBX-102 400 mg group MBX-102 600 mg group continue MBX-102 400 mg 600 mg , respectively full 24 week . All study medication over-encapsulated ; thus , patient take two blind capsule day contain either placebo , MBX-102 Actos® . This sample size provide minimum number expect ensure power least 90 % detect difference 0.64 % HbA1c placebo experimental treatment , use two-tailed , two-sample t-test type 1 error 0.05 , pool standard deviation ≤ 1.0 % , discontinuation rate ≤ 12.5 % .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients type 2 diabetes metformin last 6 month take stable dose metformin ( ≥ 1500 mg/d ) monotherapy least last 3 month Male female , 1870 year age All female patient must surgically sterile postmenopausal ( least 40 year age history menses least 2 year ; age history menses least 6 month serum FSH ≥ 40 mIU/mL ) must agree use two medically accept method contraception include barrier method . Depo contraceptives exclude . Female patient must pregnant lactate BMI ≥ 26 ( patient Asian Indian origin ≥ 22 ) kg/m2 HbA1c ≥ 7.5 % , ≤ 10.5 % FPG ≥ 120 mg/dL , ≤ 240 mg/dL History diabetes secondary pancreatitis pancreatectomy Any history ketoacidosis History insulin use within last one year ( insulin use hospitalize acceptable ) Weight loss &gt; 10 pound three month prior screen visit History TZD use ( Actos® Avandia® ) within 6 month screen visit History TZD discontinuation due side effect lack efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>